[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"vitiligo\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:vitiligo":28},{"pageToken":4,"total":5,"offset":6,"count":7,"results":8},null,30,0,25,[9,43,70,94,120,148,170,193,216,242,269,296,318,348,378,404,431,450,471,493,516,541,560,589,613],{"id":10,"slug":11,"hasResults":12,"nctId":13,"briefTitle":14,"officialTitle":15,"acronym":4,"eligibilityCriteria":16,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":24,"briefSummary":26,"conditions":27,"keywords":4,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":31,"lastUpdatePostDateStruct":32,"startDateStruct":35,"completionDateStruct":37,"leadSponsor":39,"locationsCount":42},"100633925","phase-2-a-study-of-ly4005130-in-adult-participants-with-non-segmental-vitiligo-100633925",false,"NCT07533019","A Study of LY4005130 in Adult Participants With Non-Segmental Vitiligo","A Phase 2, Randomized, 24-Week, Multicenter, Double-Blind, Placebo-Controlled Proof-of-Concept Study to Investigate Efficacy and Safety of LY4005130 in Adult Participants With Non-Segmental Vitiligo","Inclusion Criteria:\n\n* Eligible participants must have the following at both screening and baseline:\n\n  * A clinical diagnosis of non-segmented vitiligo (NSV) for at least 3 months\n  * Body surface area (BSA) involvement of 4% to 60%, inclusive, excluding involvement at palms of the hands, soles of the feet, or dorsal aspect of the feet\n  * BSA involvement of ≥0.5% on the face\n  * F-VASI ≥0.5 and T-VASI ≥3, and\n  * Either active or stable disease at both screening and baseline\n\nExclusion Criteria:\n\n* Participants who have other types of vitiligo that are not considered active or stable vitiligo\n* Currently have active forms of other disorders of pigmentation\n* Currently have active forms of inflammatory skin disease(s) or evidence of skin conditions that would interfere with evaluation of vitiligo or response to treatment\n* Have a superficial skin infection within 2 weeks before baseline. Participants may be rescreened after the infection is resolved\n* Have a history of chronic alcohol abuse, IV drug abuse, or other illicit drug abuse within 1 year prior to screening\n* Have a history or presence of cardiovascular, respiratory, hepatic, gastrointestinal, endocrine, hematological, neurological, or neuropsychiatric disorders or any other serious and\u002For unstable illness that, in the opinion of the investigator, could constitute an unacceptable risk when taking the study intervention or interfere with the interpretation of data\n* Any previous JAK inhibitor therapy, systemic or topical (for example, ruxolitinib, tofacitinib, baricitinib, upadacitinib, filgotinib, lestaurtinib, pacritinib) will NOT be allowed. Participant MUST be JAK inhibitor therapy-naïve","ALL","18 Years","75 Years",{"count":21,"type":22},60,"ESTIMATED","INTERVENTIONAL",[25],"PHASE2","The purpose of this study is to evaluate how well LY4005130 is tolerated and what side effects may occur in participants with non-segmental vitiligo (NSV) when compared with placebo. The study drug will be administered intravenously (IV) (into a vein in the arm).\n\nBlood tests will be performed to investigate how the body processes the study drug and how the study drug affects the body.\n\nThe study will last approximately 48 weeks, including screening.",[28,29],"Vitiligo","Non-Segmental Vitiligo (NSV)","RECRUITING","2026-06-19",{"date":33,"type":34},"2026-06-23","ACTUAL",{"date":36,"type":34},"2026-04-14",{"date":38,"type":22},"2027-09",{"name":40,"class":41},"Eli Lilly and Company","INDUSTRY",35,{"id":44,"slug":45,"hasResults":12,"nctId":46,"briefTitle":47,"officialTitle":48,"acronym":49,"eligibilityCriteria":50,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":51,"enrollmentInfo":52,"targetDuration":4,"studyType":23,"phases":54,"briefSummary":56,"conditions":57,"keywords":58,"overallStatus":60,"whyStopped":4,"lastUpdateSubmitDate":61,"lastUpdatePostDateStruct":62,"startDateStruct":64,"completionDateStruct":66,"leadSponsor":68,"locationsCount":4},"100641939","phase-1-a-clinical-trial-of-multiple-doses-of-gr2301-injection-combined-with-phototherapy-in-trial-participants-with-vitiligo-100641939","NCT07647237","A Clinical Trial of Multiple Doses of GR2301 Injection Combined With Phototherapy in Trial Participants With Vitiligo","A Randomized, Double-blind, Placebo-controlled Phase Ib\u002FII Clinical Trial of Multiple Subcutaneous Injections of GR2301 in Combination With Phototherapy to Evaluate the Tolerability, Safety, Pharmacokinetics, and Preliminary Efficacy in Trial Participants With Vitiligo","GREVIT","Main Inclusion Criteria:\n\n1. Meet the clinical diagnosis of non-segmental vitiligo at screening visit and baseline visit, and meet the following criteria: clinical diagnosis of non-segmental vitiligo for at least 3 months at screening visit; facial affected BSA ≥0.5% and total body affected BSA ≥3% at screening visit and baseline visit; F-VASI and T-VASI scores meet the criteria at screening visit and baseline visit.\n2. Able to understand and comply with the requirements of the clinical protocol, voluntarily participate in the clinical trial, and provide signed written informed consent by the trial participant or their legally authorized representative.\n\nMain Exclusion Criteria:\n\n1. Vitiligo-related medical conditions and other dermatologic diseases\u002Fconditions.\n2. Prior permanent tattooing or grafting within the vitiligo lesions.\n3. Have absolute contraindications to phototherapy; or have relative contraindications to phototherapy (as comprehensively judged by the investigator).\n4. Are unwilling or unable to comply with the permitted and prohibited concomitant medications\u002Ftreatment specifications of this trial, and cannot meet the protocol-required washout period for medications\u002Ftreatments prior to randomization.\n5. Have a serious underlying disease that, in the investigator's opinion, may pose a safety risk to the trial participant if enrolled in the clinical trial.","65 Years",{"count":53,"type":22},116,[55,25],"PHASE1","This is a randomized, double-blind, placebo-controlled Phase Ib\u002FII clinical trial of multiple subcutaneous injections of GR2301 in combination with phototherapy to evaluate the tolerability, safety, pharmacokinetics, and preliminary efficacy in trial participants with vitiligo. The trial will be conducted in two stages: a dose-escalation stage (Phase Ib) and an expansion cohort stage (Phase II).",[28],[59],"IL15","NOT_YET_RECRUITING","2026-06-09",{"date":63,"type":34},"2026-06-15",{"date":65,"type":22},"2026-06",{"date":67,"type":22},"2028-12",{"name":69,"class":41},"Genrix (Shanghai) Biopharmaceutical Co., Ltd.",{"id":71,"slug":72,"hasResults":12,"nctId":73,"briefTitle":74,"officialTitle":74,"acronym":4,"eligibilityCriteria":75,"healthyVolunteers":76,"sex":17,"minAge":18,"maxAge":77,"enrollmentInfo":78,"targetDuration":4,"studyType":80,"phases":4,"briefSummary":81,"conditions":82,"keywords":4,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":84,"lastUpdatePostDateStruct":85,"startDateStruct":86,"completionDateStruct":88,"leadSponsor":90,"locationsCount":93},"100330060","the-gut-and-skin-microbiome-in-vitiligo-disease-progression-100330060","NCT03577327","The Gut and Skin Microbiome in Vitiligo Disease Progression","Inclusion Criteria:\n\n* Patients with and\u002For without vitiligo lesional expansion over the past year.\n* Age\u002Fsex-matched controls who do not have a diagnosis of vitiligo\n* Subjects who are age 18-89 years of age at time of enrollment\n* Subjects who are able and willing to give informed consent for this study and the Dermatology Tissue Acquisition and Biorepository (STU00009443)\n\nExclusion Criteria:\n\n* Subjects who are younger than 18 years of age or 90 years of age or older\n* Subjects who are unable to give consent",true,"89 Years",{"count":79,"type":22},100,"OBSERVATIONAL","Investigators plan to perform a pilot study that aims to characterize the microbiome of human vitiligo patients with both active and stable disease and compare this to the microbiome of age and sex matched controls. The investigators aim to answer the question whether the gut and skin microbiome of patients with vitiligo differs from the general population.",[28,83],"Healthy","2026-06-05",{"date":61,"type":34},{"date":87,"type":34},"2019-05-30",{"date":89,"type":22},"2026-12",{"name":91,"class":92},"Northwestern University","OTHER",1,{"id":95,"slug":96,"hasResults":12,"nctId":97,"briefTitle":98,"officialTitle":99,"acronym":100,"eligibilityCriteria":101,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":51,"enrollmentInfo":102,"targetDuration":4,"studyType":23,"phases":104,"briefSummary":105,"conditions":106,"keywords":107,"overallStatus":60,"whyStopped":4,"lastUpdateSubmitDate":111,"lastUpdatePostDateStruct":112,"startDateStruct":114,"completionDateStruct":116,"leadSponsor":118,"locationsCount":93},"100640606","phase-2-a-phase-2-study-of-d-2570-in-subjects-with-non-segmental-vitiligo-100640606","NCT07625891","A Phase 2 Study of D-2570 in Subjects With Non-Segmental Vitiligo","A Phase 2 Multicenter, Randomized, Parallel-group,Double-Blind, Placebo-Controlled Study of the Safety and Efficacy of D-2570 in Subjects With Non-Segmental Vitiligo","D2570-206","Inclusion Criteria:\n\n* Voluntarily signs informed consent and complies with study procedures.\n* Age 18-65 years, male or female.\n* Clinical diagnosis of non-segmental vitiligo at screening.\n* F-VASI ≥0.25 and T-VASI ≥5 at screening and baseline, with either active or stable vitiligo.\n* Women of childbearing potential have negative pregnancy tests at screening and baseline. All eligible subjects agree to effective contraception from consent through 30 days after last study drug dose.\n\nExclusion Criteria:\n\n* \\- Segmental, mixed vitiligo or other concurrent pigmentary\u002Factive skin disorders interfering with study assessment.\n* Over 33% facial or total vitiligo lesions with leukotrichia.\n* Pregnant or breastfeeding females.\n* Active, latent or inadequately treated tuberculosis infection.\n* Positive HIV, active HBV\u002FHCV infection, or untreated syphilis.\n* Current or history of severe herpes infection.\n* Severe systemic infection requiring recent inpatient, intravenous or oral anti-infective treatment.\n* Congenital or acquired immune deficiency, opportunistic infection history, or conditions requiring systemic immunosuppression during the study.\n* Uncontrolled thyroid disease, severe cardiovascular\u002Fcerebrovascular disease or other unstable severe systemic disorders.\n* Severe psychiatric disease, suicidal ideation, or alcohol\u002Fdrug abuse within 6 months.\n* Malignancy history within 5 years (excluding cured non-melanoma skin cancer and cervical intraepithelial neoplasia).\n* Gastrointestinal disease affecting drug absorption or major surgery within 8 weeks prior to dosing.\n* Clinically significant abnormal lab results: elevated liver\u002Frenal indices, decreased hemoglobin, WBC, platelet, lymphocyte or neutrophil counts.\n* History of severe drug hypersensitivity or drug-related toxicity.\n* Any condition that may impair protocol compliance or study participation per investigator judgment.",{"count":103,"type":22},160,[25],"This study tests D-2570, an investigational drug, in people with non-segmental vitiligo to check its safety and effect on skin discoloration.\n\nEligible participants will take D-2570, or a placebo, once daily for 24 weeks in a double-blind setting. Most will then continue into a 24-week extension phase, where those on 27 mg or placebo will switch to one of the lower doses.\n\nAll participants will have a 4-week safety follow-up after treatment ends, with regular check-ups and blood tests throughout the study.",[28,29],[108,109,110],"Non-segmental Vitiligo","D-2570","Phase 2 Clinical Trial","2026-05-28",{"date":113,"type":34},"2026-06-04",{"date":115,"type":22},"2026-05-30",{"date":117,"type":22},"2028-05",{"name":119,"class":41},"InventisBio Co., Ltd",{"id":121,"slug":122,"hasResults":12,"nctId":123,"briefTitle":124,"officialTitle":125,"acronym":4,"eligibilityCriteria":126,"healthyVolunteers":12,"sex":17,"minAge":127,"maxAge":128,"enrollmentInfo":129,"targetDuration":4,"studyType":23,"phases":131,"briefSummary":133,"conditions":134,"keywords":135,"overallStatus":60,"whyStopped":4,"lastUpdateSubmitDate":139,"lastUpdatePostDateStruct":140,"startDateStruct":142,"completionDateStruct":144,"leadSponsor":146,"locationsCount":93},"100638595","phase-3-efficacy-and-safety-of-ruxolitinib-cream-in-chinese-children-aged-2-11-years-with-non-segmental-vitiligo-100638595","NCT07595939","Efficacy and Safety of Ruxolitinib Cream in Chinese Children Aged 2-11 Years With Non-segmental Vitiligo","Efficacy and Safety of Ruxolitinib Cream in Children Aged 2-11 Years With Non-segmental Vitiligo: A Single-Center, Real-World Study","Inclusion Criteria:\n\n* Children aged 2 to 11 years, regardless of sex.\n* Clinical diagnosis of non-segmental vitiligo, with affected Body Surface Area (BSA) ≥0.1%, T-VASI score ≥0.1, and total depigmented area not exceeding 10% BSA.\n* Legal guardian voluntarily provides signed informed consent and agrees to scheduled follow-ups.\n\nExclusion Criteria:\n\n* Diagnosis of other forms of vitiligo (e.g., segmental vitiligo).\n* Presence of other hypopigmentary or depigmentary disorders that could interfere with efficacy assessment (e.g., pityriasis alba, leprosy, post-inflammatory hypopigmentation, progressive macular hypomelanosis, nevus depigmentosus, and tinea versicolor).\n* Prior or current use of any treatment for depigmentation.\n* History of failure with any systemic or topical JAK inhibitor therapy for vitiligo or any other inflammatory condition.\n* Known hypersensitivity to the study drug or its excipients.\n* Concurrent participation in another clinical trial.\n* Considered by the investigator to be unsuitable for the study for any other reason.","2 Years","11 Years",{"count":130,"type":22},20,[132],"PHASE3","The goal of this clinical trial is to evaluate the efficacy and safety of Ruxolitinib Phosphate Cream in treating non-segmental vitiligo in children aged 2 to 11 years under real-world conditions. The main question\\[s\\] it aims to answer are:\n\nPrimary Efficacy: What is the improvement rate (e.g., proportion of participants achieving F-VASI75) after 24 weeks of treatment with Ruxolitinib Phosphate Cream in this population? Safety Profile: What is the safety profile of the treatment over 24 weeks, specifically regarding the incidence of Application Site Acne, Application Site Pruritus, and other adverse events?\n\nParticipants will:\n\nApply Ruxolitinib Phosphate Cream topically to vitiligo lesions as prescribed by the investigator.\n\nAttend scheduled clinic visits at Weeks 4, 8, 12, and 24 for efficacy and safety assessments.\n\nUndergo standardized clinical photography and severity scoring of their vitiligo lesions at each visit.\n\nReport any adverse events or skin reactions experienced during the study period to the research team.",[28],[136,137,138],"vitiligo","Ruxolitinib","children","2026-05-18",{"date":141,"type":34},"2026-05-19",{"date":143,"type":22},"2026-06-01",{"date":145,"type":22},"2028-12-31",{"name":147,"class":92},"The Children's Hospital of Zhejiang University School of Medicine",{"id":149,"slug":150,"hasResults":12,"nctId":151,"briefTitle":152,"officialTitle":153,"acronym":154,"eligibilityCriteria":155,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":156,"targetDuration":4,"studyType":23,"phases":158,"briefSummary":159,"conditions":160,"keywords":4,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":139,"lastUpdatePostDateStruct":161,"startDateStruct":163,"completionDateStruct":165,"leadSponsor":167,"locationsCount":169},"100604677","phase-2-combination-approach-with-ritlecitinib-and-nbuvb-compared-to-ritlecitinib-alone-for-treating-vitiligo-100604677","NCT07152626","Combination Approach With Ritlecitinib and nbUVB Compared to Ritlecitinib Alone for Treating Vitiligo","Combination Approach With Ritlecitinib and nbUVB Compared to Ritlecitinib Alone for Treating Vitiligo Prospective Multicentric Evaluator Blinded Interventional Study","COMBIVIT","Inclusion Criteria:\n\n* 1\\. Men and women with non-segmental vitiligo. 2. Age ≥ 18 age old 3. BSA involvement between 4% and 60% inclusive, excluding involvements at palms of the hands, soles of the feet, or dorsal aspect of the feet 4. BSA ≥0.5% involvement on the face (face is defined as including the area on the forehead to the original hairline, on the cheek vertically to the jawline, and laterally from the corner of the mouth to the tragus. The face will not include scalp, ears, neck, or surface area of the lips, but will include the nose and the eyelids) 5. F-VASI ≥0.5 and T-VASI ≥3 6. Active and stable vitiligo 7. For Women of childbearing potential (WOCBP), an effective contraception (estroprogestative pill, contraceptive implant, IUD, condoms or tubal ligation) should be used for more than one month before the inclusion in the study; Women of childbearing potential (WOCBP) must have a negative urine pregnancy test result at baseline; WOCBP are defined as women who are biologically capable of becoming pregnant, including women who are using contraceptives or whose sexual partners are either sterile or using contraceptives;\n\nWomen of non-childbearing potential (WONCBP) do not require a urine pregnancy test and must meet at least one of the following criteria:\n\no Have undergone hysterectomy or bilateral oophorectomy;\n\n* Have medically confirmed ovarian failure; or\n* Are medically confirmed to be post-menopausal (cessation of regular menses for at least 12 consecutive months with no alternative pathological or physiological cause); 8. Affiliation to a social security system; 9. Signed informed consent.\n\nExclusion Criteria:\n\n* 1\\. Pregnant or breast-feeding women. Or women with potential childbearing and not taking contraceptives or who plan to get pregnant during the study duration, and 2. Segmental or mixed vitiligo, and 3. Contraindication to nbUVB phototherapy, and 4. Concomitant use of topical or systemic immunosuppressive medication or steroids, and 5. Patients treated before with oral JAK inhibitor, topical treatments (including JAK inhibitors) that could affect vitiligo (eg, corticosteroids, vitamin D3 and calcineurin inhibitor) within 2 Weeks of Day 1 (Baseline) and during the study\n\nAt any time prior to or during the study:\n\n* Use of permanent depigmentation treatment for vitiligo and\u002For other types of pigmentation disorder (eg, monobenzone or phenol).\n* Previous use of any systemic JAK inhibitor for any disease indication\n* Any non-B cell selective lymphocyte depleting agent (eg, alefacept, alemtuzumab) and alkylating agents \\[eg, cyclophosphamide or chlorambucil\\], total lymphoid irradiation, etc.\n* History of MKTP or other surgical treatment for vitiligo.\n\nWithin 6 months of the first dose of study drug or 5 half-lives (if known), or until lymphocyte count returns to normal, whichever is longer and during the study:\n\n\\- Any B-cell-depleting agents including but not limited to rituximab or previously receiving leukocyte apheresis, including selective lymphocyte, monocyte, or granulocyte apheresis, or plasma exchange.\n\nWithin 12 weeks of first dose of study drug or 5 half-lives (if known), whichever is longer and during the study:\n\n* Other immunomodulatory biologic agents or other marketed immunosuppressants.\n* IL12\u002F23 inhibitor (eg, ustekinumab)\n* Integrin inhibitors (eg, vedolizumab)\n\nWithin 8 weeks of Day 1 and during the study:\n\n\\- Narrow-band UVB phototherapy, Psoralen Ultra-Violet A therapy, or other phototherapy.\n\nTNF inhibitors (or biosimilars thereof) as described below:\n\n* Infliximab;\n* Adalimumab;\n* Golimumab\n* Interferon therapy\n\nWithin 8 Weeks of Day 1 \\[Baseline\\] (or within 5 half-lives, whichever is longer) and during the study:\n\n* Systemic treatments that could affect vitiligo.\n* Use of oral or intravenous immune suppressants (eg, cyclosporine A, tacrolimus, azathioprine, MTX, systemic corticosteroids, mycophenolate-mofetil, mercaptopurine (6MP), or thioguanine).\n* Use of sulfasalazine.\n* Intralesional, oral or injectable steroids.\n\nWithin 6 Weeks of Day 1 (Baseline), during the study, and within 6 weeks of last dose:\n\n\\- Vaccination with live attenuated, replication-competent vaccine; Current routine household contact with individuals who have been vaccinated with a live attenuated, replication-competent vaccine.\n\nWithin 4 weeks (28 Days) of first dose of study intervention or 5 half-lives (if known), whichever is longer and during the study:\n\n* Prohibited CYP3A inducers (see Table 8).\n* Herbals that are known to have an effect on drug metabolism.\n* Previous administration of investigational drug(s) or vaccines that do not affect vitiligo.\n\nNote: Any investigational or experimental therapy taken, or procedure performed for vitiligo and other autoimmune or immunologic diseases including but not limited to rheumatoid arthritis, psoriasis alopecia areata, thyroid disease, allergic rhinitis, or atopic dermatitis within the previous 1 year should be carefully evaluated. Participants cannot participate in studies of other investigational or experimental therapies or procedures at any time during their participation in this study.\n\nWithin 1 Week of Day 1 \\[Baseline\\] (or within 5 half-lives, whichever is longer) and during the study:\n\n\\- Herbal medications with unknown properties or known beneficial effects for vitiligo.\n\n* Prohibited CYP3A substrates as described in Table 8.\n* Investigators should consult the SRSD for ritlecitinib for information regarding medication that is prohibited for concomitant use.\n* Investigators should consult the product label for any other medication used during the study for information regarding medication that is prohibited for concomitant use.\n\nAnd 6. Patients suffering from photodermatosis or taking photosensitive drugs, and 7. Patients with more than 33% of leucotrichia on the lesions (Leukotrichia in more than 33% of the face surface area affected with vitiligo lesions OR leukotrichia in more than 33% of the total body surface area affected with vitiligo lesions), and 8. Personal history of skin cancer, and 9. Personal history of any malignancies or a history of malignancies with the exception of adequately treated or excised nonmetastatic basal cell or squamous cell cancer of the skin or cervical carcinoma in situ will be excluded from the study, and 10. Patients with active infection or other systemic\u002F inflammatory disease, and 11. Tuberculosis or latent tuberculosis, and 12. Vulnerable people: pregnant or breast-feeding women, minors, adult under guardianship, deprived of freedom or with psychiatric condition, and 13. Participants in other clinical therapeutic studies involving a drug that could interfere with the present evaluation.\n\n14\\. Participants are excluded from the study if any of the following criteria apply: i. Medical Conditions:\n\n* Any psychiatric condition including recent or active suicidal ideation or behavior that meets any of the following criteria:\n* Suicidal ideation associated with actual intent and a method or plan in the past year: \"Yes\" answers on items 4 or 5 of the C-SSRS administered at the Screening visit (see Appendix 6).\n* Previous history of suicidal behaviors in the past 5 years: \"Yes\" answer (for events that occurred in the past 5 years) to any of the suicidal behavior items of the C-SSRS.\n* For adults, any lifetime history of serious suicidal behavior or recurrent suicidal behavior. For adolescents, any previous lifetime history of suicidal behavior.\n\nii. Medical conditions pertaining to vitiligo and other diseases\u002Fconditions affecting the skin:\n\n* Participants that have other types of vitiligo that do not meet criteria for active or stable vitiligo as noted in inclusion criterion #2 (including, but not limited to, segmental vitiligo and mixed vitiligo).\n* Currently have active forms of other disorders of pigmentation (including but not limited to Vogt-Koyanagi-Harada disease, malignancy-induced hypopigmentation \\[melanoma and mycosis fungoides\\], post-inflammatory hypopigmentation, pityriasis alba \\[minor manifestation of atopic dermatitis\\], senile leukoderma \\[age-related depigmentation\\], chemical\u002Fdrug-induced leukoderma, ataxia telangiectasia, tuberous sclerosis, melasma (all types, including mixed), and congenital hypopigmentation disorder including piebaldism, Waardenburg syndrome, hypomelanosis of Ito, incontinentia pigmenti, dyschromatosis symmetrica hereditarian, xeroderma pigmentosum, and nevus depigmentosus). NOTE: Coexistence of halo nevus\u002Fnevi (also known as Sutton nevus\u002Fnevi) is permitted.\n* Currently have active forms of inflammatory skin disease(s) or evidence of skin conditions (for example, morphea, discoid lupus, leprosy, syphilis, psoriasis, seborrheic dermatitis) at the time of the Screening or Baseline Visit that in the opinion of the investigator would interfere with evaluation of vitiligo or response to treatment.\n* Have a superficial skin infections within 2 weeks prior to first dose on Day 1. NOTE: participants may be rescreened after the infection resolves.\n\niii. General Infection History:\n\n* Having a history of systemic infection requiring hospitalization, parenteral antimicrobial, antiviral (including biologic treatment), antiparasitic, antiprotozoal, or antifungal therapy, or as otherwise judged clinically significant by the investigator within 6 months prior to Day 1.\n* Have active acute or chronic infection requiring treatment with oral antibiotics, antivirals, antiparasitics, antiprotozoals, or antifungals within 4 weeks prior to Day 1. NOTE: participants may be rescreened after the infection resolves.\n* Evidence or history of untreated, currently treated or inadequately treated active or latent infection with Mycobacterium TB as evidenced by the following:\n* IGRA test: a positive QFT-G during Screening (completed by central laboratory) or a positive or borderline T-SPOT®TB (performed at local laboratory in Japan, China or those countries where local guidance require T-SPOT®TB testing) during Screening. If the IGRA test results are indeterminate\u002Fborderline, the test should be repeated. If the results of the repeat test are indeterminate\u002Fborderline, a PPD test may be substituted for the IGRA test only with the approval from the Pfizer medical monitor on a case-by-case basis. (Participants with a history BCG vaccination must have a negative IGRA test).\n* A positive QFT-G test or positive or borderline T-SPOT®TB (T-SPOT test) performed within 12 weeks prior to Screening.\n* Assessment of the Screening chest imaging for latent or active tuberculosis is required if QFT-G is positive or T-SPOT is positive or borderline or if the participant has been previously treated for latent or active TB and is to be performed according to local standards of care or country-specific guidelines. Chest imaging performed 12 weeks prior to Screening showing no active TB will be accepted with a copy of the report available in the source document.\n\nNOTE: Participants who have previously been adequately treated for latent or active TB (according to WHO\u002Fregional or local country recommendations by appropriately qualified personnel as defined by local practice) may be enrolled. Neither a QFT-G test, nor a TSPOT test nor a PPD test is needed provided the treatment, including details of the previous course of therapy (eg, medication(s) used, dose, and duration) is well documented in the participant's medical records and\u002For source documentation prior to enrollment in the study. A participant who is currently being treated for latent TB infection can only be enrolled with documentation of an adequate treatment regimen that does not include prohibited medications (such as rifamycins \\[eg, Rifabutin, Rifampin, Rifapentine\\]), and with prior approval by the sponsor (see Section 8.7).\n\niv. Specific Viral Infection History:\n\n* History (single episode) of disseminated herpes zoster or disseminated herpes simplex, or a recurrent (more than one episode of) localized, dermatomal herpes zoster.\n* Infected with hepatitis B or hepatitis C viruses: all participants will undergo screening for hepatitis B and C for eligibility.\n* Hepatitis B: At Screening, hepatitis B surface antigen (HBsAg) and hepatitis B core antibody (HBcAb) will be tested:\n* If both tests are negative, the participant is eligible for study inclusion.\n* If HBsAg is positive, the participant must be excluded from participation in the study.\n* If HBsAg is negative and HBcAb is positive, hepatitis B surface antibody (HBsAb) reflex testing is required:\n\n  1. If HBsAb is negative, the participant must be excluded from participation in the study; OR\n  2. If HBsAb is positive, the participant is eligible for study inclusion.\n* Hepatitis C: At Screening, hepatitis C antibody (HCVAb) will be tested:\n* Participants who are HCVAb negative are eligible.\n* Participants who are HCVAb positive will be reflex-tested for hepatitis C (HCV) RNA. Participants who are positive for HCVAb and HCV RNA will not be eligible for this study.\n* Have a known immunodeficiency disorder (including positive serology for HIV at Screening) or a first-degree relative with a hereditary immunodeficiency.\n\n  v. Medical Conditions, Other:\n* Current or recent history of clinically significant severe, progressive, or uncontrolled renal (including but not limited to active renal disease or recent kidney stones), hepatic, hematological, gastrointestinal, metabolic, endocrine (eg, untreated hypovitaminosis D or hypothyroidism), pulmonary, cardiovascular, psychiatric, immunologic\u002Frheumatologic or neurologic disease; or have any other severe acute or chronic medical or psychiatric condition or laboratory abnormality that may increase the risk associated with study participation or investigational product administration, or interfere with the interpretation of study results; or in the opinion of the investigator or Pfizer (or designee), the participant is inappropriate for entry into this study, or unwilling\u002Funable to comply with study procedures and lifestyle requirements.\n\nNote: In case hypovitaminosis D (under LLN) is identified for the first time at Screening, treatment should be started at least 7 days prior to baseline.\n\n• History of severe allergic or anaphylactoid reaction to any kinase inhibitor or a known allergy\u002Fhypersensitivity to any component (including excipients) of the study intervention.\n\n* Have hearing loss with progression over the previous 5 years, sudden hearing loss, or middle or inner ear disease such as otitis media, cholesteatoma, Meniere's disease, labyrinthitis, or other auditory condition that is considered acute, fluctuating or progressive.\n* Have a history of any lymphoproliferative disorder such as EBV-related lymphoproliferative disorder, history of lymphoma, history of leukemia, or signs and symptoms suggestive of current lymphatic or lymphoid disease.\n* Abnormal findings on the screening chest imaging (eg, chest x-ray) that may increase the risk associated with study participation including, but not limited to, presence of active TB, general infections, cardiomyopathy, or malignancy. Chest imaging may be performed up to 12 weeks prior to Screening. Documentation of the official reading must be located and available in the source documentation.\n* Long QT Syndrome, a family history of Long QT Syndrome, or a history of TdP.\n* Have any malignancies or have a history of malignancies with the exception of adequately treated or excised nonmetastatic basal cell or squamous cell cancer of the skin or cervical carcinoma in situ.\n* Significant trauma or major surgery within 1 month of the first dose of study drug or considered in imminent need for surgery or with elective surgery scheduled to occur during the study.\n\n  15\\. Patients with severe hepatic impairment.",{"count":157,"type":22},56,[25],"Vitiligo affects approximately 1 to 2% of the global population and significantly impacts people's quality of life. areas of high stress. Ritlecitinib, an orally administered inhibitor of JAK3 (Janus kinase)\u002F TEC (tyrosine kinase expressed in hepatocellular carcinoma) has shown effectiveness and safety for the treatment of vitiligo. In a phase 2b trial, three doses of ritlecitinib, 200\u002F50 mg, 100\u002F50 mg, and 50 mg, were all statistically significant versus placebo on the Facial Vitiligo Area Scoring Index (F-VASI) at week 24 in patients with active NSV. Considering that the immune process primarily contributes to depigmentation while ultraviolet (UV) radiation stimulates the differentiation and proliferation of melanocyte stem cells for re-pigmentation, the investigators propose that a combination therapy using ritlecitinib and narrowband UVB (nbUVB) could offer an optimal approach for treating vitiligo patients.\n\nThe primary objective is thTo compare between the groups, the mean percentage change from baseline in F-VASI and T-VASI at week 52.\n\nFollowing central randomization, patients will be assigned to receive either ritlecitinib 100mg daily (QD) or a combined therapy using ritlecitinib 100mg QD + twice weekly narrowband UVB treatment for a duration of 52 weeks. At the end of this period, all participants will continue for the open-label phase, receiving ritlecitinib 100mg QD. Eligible participants will be stratified by Fitzpatrick Skin Type (FST, also known as phototype). More specifically, there will be 2 strata based on FST targets: (1) FST I to III (2) FST I IV, to VI. Each FST stratum will target to enroll at least 50% participants into the study population. Stratified randomization across FST sub-groups will support the evaluation of a consistent benefit-risk profile across all FST strata. Enrollment of participants with active or stable nonsegmental vitiligo will be proactively managed without formally capping or stratifying.\n\nThroughout the study, there will be a total of 8 visits conducted: selection, inclusion, week 4, week 12, week 24, week 36, week 52 and week 72. In patients who volunteer, a skin biopsy will be performed on both the lesional and perilesional areas at baseline, week 4 and week 52. We aim to include between 12 and 20 volunteer patients. Serum and plasma samples will be collected at the screening visit, week 4, week 12, week 24, week 36, week 52 and week 72.\n\nA pregnancy test will be performed every 4 weeks i.e. at weeks 8, 16, 20, 28, 32, 40, 44, 48, 56, 60, 64 and 68;",[28],{"date":162,"type":34},"2026-05-20",{"date":164,"type":34},"2026-03-12",{"date":166,"type":22},"2029-06-01",{"name":168,"class":92},"Centre Hospitalier Universitaire de Nice",5,{"id":171,"slug":172,"hasResults":12,"nctId":173,"briefTitle":174,"officialTitle":175,"acronym":176,"eligibilityCriteria":177,"healthyVolunteers":12,"sex":17,"minAge":4,"maxAge":4,"enrollmentInfo":178,"targetDuration":179,"studyType":80,"phases":4,"briefSummary":180,"conditions":181,"keywords":4,"overallStatus":60,"whyStopped":4,"lastUpdateSubmitDate":183,"lastUpdatePostDateStruct":184,"startDateStruct":186,"completionDateStruct":188,"leadSponsor":190,"locationsCount":93},"100532843","vitiligo-registry-for-adults-and-children-in-the-uk-100532843","NCT06218082","Vitiligo Registry for Adults and Children in the UK","Vitiligo Registry for Adults and Children in the UK (VIRTUAL-UK)","VIRTUAL-UK","Inclusion Criteria:\n\n1. Paediatric and adult patients with vitiligo under management in secondary care.\n2. Written informed consent for study participation obtained from the patient or parents \u002F legal guardian, with assent as appropriate by the patient, depending on the level of understanding.\n3. Participants consent to participate in long-term follow up and access to all relevant medical records as needed by the study team\n4. Clinical diagnosis of vitiligo made by a dermatologist\n5. Willingness to comply with all study requirements.\n6. Competent use of English language, according to patient's age (capable of understanding patient questionnaires).\n\nExclusion Criteria:\n\n1. Insufficient understanding of the study by the patient and\u002For parent\u002Fguardian.\n2. Patients with vitiligo\u002Ftheir parents or guardians, who do not provide consent for participation.",{"count":5,"type":22},"1 Year","Vitiligo is the most common depigmentation disorder affecting around 1% of the population worldwide. Fifty two percent of patients develop vitiligo before the age of 20 and around 80% develop vitiligo before the age of 30 years old.1 Vitiligo often presents in childhood and tends to be a lifelong disease, requiring prolonged courses of phototherapy.\n\nCurrently no national or international registry for patients with vitiligo exists. Individual dermatologists maintain a database of such patients, however no coordinated efforts have been made to combine these individual registries into a broader national registry. Finally, recently published British Association of Dermatologists (BAD) guideline for the management of vitiligo, recommended the development of a national registry for people with vitiligo undergoing systemic or light therapy to identify outcomes and safety.",[182,28],"Dermatologic Disease","2026-04-08",{"date":185,"type":34},"2026-04-09",{"date":187,"type":22},"2026-05-15",{"date":189,"type":22},"2030-02",{"name":191,"class":192},"The Royal Wolverhampton Hospitals NHS Trust","OTHER_GOV",{"id":194,"slug":195,"hasResults":12,"nctId":196,"briefTitle":197,"officialTitle":198,"acronym":199,"eligibilityCriteria":200,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":51,"enrollmentInfo":201,"targetDuration":4,"studyType":23,"phases":203,"briefSummary":204,"conditions":205,"keywords":4,"overallStatus":60,"whyStopped":4,"lastUpdateSubmitDate":208,"lastUpdatePostDateStruct":209,"startDateStruct":210,"completionDateStruct":212,"leadSponsor":214,"locationsCount":93},"100632849","phase-1-study-of-umbilical-cord-mesenchymal-stem-cell-derived-exosomes-in-vitiligo-100632849","NCT07519031","Study of Umbilical Cord Mesenchymal Stem Cell-Derived Exosomes in Vitiligo","A Single-Center, Randomized, Controlled Trial of Human Umbilical Cord Mesenchymal Stem Cell-Derived Exosomes for the Treatment of Vitiligo","hUMSCs-Exo-VIT","Inclusion Criteria:\n\n* Clinically diagnosed non-segmental vitiligo\n* Progressive vitiligo: new lesions or enlargement of existing lesions within the past 3 months (VIDA score ≥ 3); Stable vitiligo: no new lesions or enlargement of existing lesions within the past 1 year (VIDA score = 0)\n* Total body surface area (BSA) of vitiligo lesions between 1% and 30%\n* Age 18 to 65 years, male or female\n* Willing to participate and provide written informed consent\n\nExclusion Criteria:\n\n* Pregnancy or breastfeeding\n* Known allergy to mesenchymal stem cells or exosome components\n* Severe cardiac, hepatic, or renal dysfunction, or severe immunocompromised status\n* For progressive vitiligo: use of systemic immunosuppressants, corticosteroids, phototherapy, or photochemotherapy within the past 3 months\n* For stable vitiligo: use of phototherapy, topical immunosuppressants, or corticosteroids within the past 1 month\n* Concurrent autoimmune diseases (e.g., systemic lupus erythematosus, rheumatoid arthritis, psoriasis) or severe infectious diseases\n* History of malignancy or hematologic disorders\n* History of psychiatric disorders or inability to comply with study procedures\n* Any other condition that, in the investigator's judgment, may increase the risk to the participant or interfere with the conduct of the trial",{"count":202,"type":22},96,[55,25],"This study evaluates whether exosomes derived from human umbilical cord mesenchymal stem cells (hUMSCs-Exo) are safe and effective for treating vitiligo in adults.\n\nVitiligo is a skin condition that causes white patches due to loss of pigment-producing cells. Current treatments have limitations, especially for patients with active disease who require oral steroids with significant side effects.\n\nThis study is a single-center, randomized, controlled trial enrolling 96 adults aged 18 to 65 years with non-segmental vitiligo. Participants are divided into two groups based on disease activity: progressive vitiligo (new patches appearing or existing patches expanding in the past 3 months) and stable vitiligo (no changes in the past year).\n\nFor progressive vitiligo, participants are randomly assigned to either:\n\nExperimental group: hUMSCs-Exo given by intravenous infusion every 2 weeks for 5 sessions, plus tacrolimus ointment and narrowband UVB light therapy, or Control group: oral prednisone (a standard steroid treatment) plus tacrolimus ointment and narrowband UVB light therapy\n\nFor stable vitiligo, participants are randomly assigned to either:\n\nExperimental group: hUMSCs-Exo given by local injection into the white patches every 2 weeks for 5 sessions, plus tacrolimus ointment and narrowband UVB light therapy, or Control group: tacrolimus ointment plus narrowband UVB light therapy alone The treatment period lasts 12 weeks, with follow-up visits continuing to 24 weeks. The main outcome measures include improvement in skin repigmentation measured by the Vitiligo Area Scoring Index (VASI), changes in quality of life, and safety monitoring throughout the study.\n\nThis study aims to establish a standardized approach for using hUMSCs-Exo in vitiligo treatment and to explore how exosomes may work by reducing oxidative stress and regulating immune responses.",[28,206,207],"Mesenchymal Stem Cells","Exosomes","2026-04-01",{"date":185,"type":34},{"date":211,"type":22},"2026-04",{"date":213,"type":22},"2028-03",{"name":215,"class":92},"Xijing Hospital",{"id":217,"slug":218,"hasResults":12,"nctId":219,"briefTitle":220,"officialTitle":220,"acronym":28,"eligibilityCriteria":221,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":222,"enrollmentInfo":223,"targetDuration":4,"studyType":23,"phases":225,"briefSummary":226,"conditions":227,"keywords":228,"overallStatus":60,"whyStopped":4,"lastUpdateSubmitDate":233,"lastUpdatePostDateStruct":234,"startDateStruct":236,"completionDateStruct":238,"leadSponsor":240,"locationsCount":93},"100632096","phase-2-comparative-efficacy-of-hucmsc-secretome-delivered-via-microneedling-and-intradermal-microinjection-as-adjuvant-therapy-to-nb-uvb-in-nonsegmental-vitiligo-a-quasi-experimental-study-100632096","NCT07509242","Comparative Efficacy of hUCMSC-Secretome Delivered Via Microneedling and Intradermal Microinjection as Adjuvant Therapy to NB-UVB in Nonsegmental Vitiligo: A Quasi-Experimental Study","Inclusion Criteria:\n\n* Patients with a diagnosis of non-segmental vitiligo (established by a dermatologist).\n* Age 18-60 years.\n* Fitzpatrick skin types III-V.\n* Stable vitiligo lesions for at least 6 months (no new lesions and no lesion expansion \\>10% of body surface area within the past 6 months).\n* Total lesion involvement of 1-20% body surface area (BSA).\n* Willing to comply with the full course of therapy and all scheduled follow-up visits during the study.\n* Provision of written informed consent.\n\nExclusion Criteria:\n\n* Segmental, universal, or other vitiligo types that are difficult to standardize (e.g., lesions limited to the genital area).\n* Currently receiving or having received within the past 3 months:\n* Systemic immunomodulatory or immunosuppressive therapy (e.g., systemic corticosteroids, cyclosporine, methotrexate, JAK inhibitors, etc.).\n\nOther phototherapy modalities (e.g., PUVA, excimer laser) within the past 3 months.\n\n* History of keloid formation or hypertrophic scarring at the treatment sites.\n* Active infection at the lesion sites (bacterial, viral, or fungal) or other skin diseases that may interfere with pigmentation assessment.\n* Pregnancy or breastfeeding.\n* History of skin cancer, lupus, or other photosensitive disorders.\n* Severe allergy to secretome components or gel excipients (if known).\n* Uncontrolled systemic diseases (e.g., heart failure, renal failure, active systemic autoimmune disease) that may compromise follow-up compliance.","60 Years",{"count":224,"type":22},150,[25,132],"The goal of this clinical trial is to analyze the effectiveness of SM-hUCMSC secretome administered via microneedling and intradermal microinjection as adjuvant therapy to NB-UVB, compared with NB-UVB alone, in terms of repigmentation, onset of improvement, safety, patient satisfaction, and vitiligo recurrence. The main questions it aims to answer are:\n\n* Are there differences in the level of vitiligo lesion repigmentation among the secretome therapy via microneedling, intradermal microinjection, and NB-UVB phototherapy groups?\n* Are there differences in the time to onset of repigmentation among the treatment groups? What are the safety profiles and adverse events associated with each treatment modality?\n* Are there differences in patient satisfaction and quality of life after undergoing each therapy?\n* Are there differences in vitiligo recurrence rates during the follow-up period among the treatment groups?\n\nParticipants will be allocated into three groups as follows:\n\n* Group A receives NB-UVB combined with microneedling and topical 10% secretome.\n* Group B receives NB-UVB combined with intradermal secretome injection.\n* Group C receives NB-UVB alone. The intervention period lasts 12 weeks, with follow-up until week 24.",[28],[229,230,231,232,28],"Dermatology","Microneedling","NB-UVB","Secretome","2026-03-28",{"date":235,"type":34},"2026-04-03",{"date":237,"type":22},"2026-03-18",{"date":239,"type":22},"2028-01-18",{"name":241,"class":92},"Yohanes Firmansyah, dr, MH, MM",{"id":243,"slug":244,"hasResults":12,"nctId":245,"briefTitle":246,"officialTitle":247,"acronym":4,"eligibilityCriteria":248,"healthyVolunteers":12,"sex":17,"minAge":249,"maxAge":4,"enrollmentInfo":250,"targetDuration":4,"studyType":23,"phases":251,"briefSummary":253,"conditions":254,"keywords":255,"overallStatus":60,"whyStopped":4,"lastUpdateSubmitDate":164,"lastUpdatePostDateStruct":261,"startDateStruct":263,"completionDateStruct":265,"leadSponsor":267,"locationsCount":93},"100629295","phase-4-the-value-of-adding-mini-oral-pulse-steroid-therapy-in-preventing-peri-lesional-halo-post-non-cultured-epidermal-cell-suspension-nces-in-cases-with-stable-segmental-and-non-acral-vitiligo-100629295","NCT07472816","The Value of Adding Mini-oral Pulse Steroid Therapy in Preventing Peri-lesional Halo Post Non-cultured Epidermal Cell Suspension (NCES) in Cases With Stable Segmental and Non-acral Vitiligo.","The Value of Adding Mini-oral Pulse Steroid Therapy in Preventing Peri-lesional Halo Post Non-cultured Epidermal Cell Suspension (NCES) in Cases With Stable Segmental and Non-acral Vitiligo: An Interventional Prospective Randomized Controlled Trial.","Inclusion criteria:\n\n* Patients with segmental vitiligo lesions that are not responsive to conventional treatment.\n* Patients with non-Acral vitiligo lesions that are not responsive to conventional treatment and on sites known to be responsive to surgery, like the face and trunk.\n* Stability for ≥ 1 year.\n* Age ≥12 years.\n* Lack of systemic and topical treatment for at least 3 months prior inclusion in the study.\n\nExclusion criteria:\n\n* Acral vitiligo.\n* Segmental vitiligo lesions that are responsive to conventional treatment.\n* Non acral vitiligo lesions on sites that are knowingly not responsive to surgery, like knees and elbows.\n* Active vitiligo; new lesions, expansion of old lesions, confetti like lesions, ill-defined edges, hypochromia, depigmentation of previously pigmented areas or koebnerization in \\\u003C 1 year.\n* Age \\\u003C 12 years.\n* Pregnant females.\n* Patients with contraindication to systemic steroid like uncontrolled hypertension, diabetes or tuberculosis\n* Systemic and topical treatment in the past 3 months.","12 Years",{"count":21,"type":22},[252],"PHASE4","The goal of this clinical trial is to learn if adding mini-oral pulse steroid therapy improves the results of non-cultured epidermal cell suspension (NCES) surgery in patients with stable vitiligo. It will also evaluate the safety of this treatment approach. The main questions it aims to answer are:\n\n* Does adding mini-oral pulse steroid therapy reduce the development of a perilesional halo after NCES surgery?\n* Does the addition of steroids improve the degree of repigmentation and overall treatment outcomes in vitiligo lesions?\n\nResearchers will compare NCES surgery with mini-oral pulse steroids to NCES surgery alone to determine whether the steroid therapy improves surgical outcomes.\n\nParticipants will:\n\n* Undergo NCES vitiligo surgery for stable segmental or non-acral vitiligo lesions.\n* Be randomly assigned to receive either surgery alone or surgery plus low-dose oral mini-pulse dexamethasone therapy.\n* Attend follow-up visits and clinical assessments for approximately 4 months.\n* Receive excimer laser sessions twice weekly after healing and have standardized photographs and scoring assessments to evaluate repigmentation.",[28],[256,28,257,258,259,260],"non-cultured epidermal cell suspension","Segmental","non-acral","Mini-oral pulse steroid","peri-lesional halo",{"date":262,"type":34},"2026-03-16",{"date":264,"type":22},"2026-03-15",{"date":266,"type":22},"2026-07-01",{"name":268,"class":92},"Cairo University",{"id":270,"slug":271,"hasResults":12,"nctId":272,"briefTitle":273,"officialTitle":274,"acronym":4,"eligibilityCriteria":275,"healthyVolunteers":12,"sex":17,"minAge":276,"maxAge":277,"enrollmentInfo":278,"targetDuration":4,"studyType":23,"phases":280,"briefSummary":282,"conditions":283,"keywords":284,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":287,"lastUpdatePostDateStruct":288,"startDateStruct":290,"completionDateStruct":292,"leadSponsor":294,"locationsCount":93},"100623605","early-phase-1-effectiveness-of-micro-needling-with-5-fluorouracil-versus-potent-topical-steroids-in-the-treatment-of-limited-vitiligo-100623605","NCT07398807","Effectiveness of Micro-needling With 5 Fluorouracil Versus Potent Topical Steroids in the Treatment of Limited Vitiligo","Effectiveness of Combining Micro Needling With 5 Fluorouracil Versus Potent Topical Steroids; in Treating Limited Vitiligo- Randomised Controlled Study","Inclusion Criteria:\n\n* Patients willing to participate in the study\n* Patients of age group of 05 -70 years.\n* Vitiligo involving less than or equal to 10% body surface area.\n\nExclusion Criteria:\n\n* Patients using or have used other treatments for vitiligo\n* Pregnant women or lactating women\n* Patients with unstable vitiligo\n* Patients on immunosuppressant medications due to other diseases\n* Patients having anemia, immunosuppression, bleeding disorder, taking anticoagulants or anti-platelet drugs or having epilepsy\n* Patient having history of keloids or hypertrophic scars\n* Patients with history of hypersensitivity to either of the drugs","4 Years","70 Years",{"count":279,"type":22},40,[281],"EARLY_PHASE1","The goal of this clinical trial is to learn how well 5 fluorouracil (5FU) with micro-needling works to treat limited vitiligo as compared to strong steroid applied on skin. It will also learn about the safety of both these treatments. The main questions it aims to answer are:\n\n* How well does 5FU with microneedling work to treat vitiligo by returning pigmentation in vitiligo patches as compared to steroid?\n* What is participant's satisfaction when treated with 5FU with microneedling as compared to steroid?\n* What skin problems do participants have when treated with FU with microneedling and steroid?\n\nResearchers will compare 5FU with microneedling to steroid application to see how well both work to return pigment in vitiligo patches.\n\nParticipants will be divided into two groups. For Group A, 5 FU will be rubbed and absorbed on the vitiligo patch after micro-needling every 2 weeks.\n\nFor group B, topical 0.05% clobetasol propionate ointment will be applied twice a day on the vitiligo patches for 12 weeks.\n\nVitiligo patches will be assessed at the start of trial and then after 12 weeks of treatment.",[28],[28,285,230,286],"Limited","5-FU","2026-02-12",{"date":289,"type":34},"2026-02-17",{"date":291,"type":34},"2025-08-08",{"date":293,"type":22},"2026-02",{"name":295,"class":92},"Combined Military Hospital (CMH) institute of Medical Sciences Bahawalpur Pakistan",{"id":297,"slug":298,"hasResults":12,"nctId":299,"briefTitle":300,"officialTitle":301,"acronym":4,"eligibilityCriteria":302,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":222,"enrollmentInfo":303,"targetDuration":4,"studyType":23,"phases":305,"briefSummary":306,"conditions":307,"keywords":4,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":308,"lastUpdatePostDateStruct":309,"startDateStruct":311,"completionDateStruct":313,"leadSponsor":315,"locationsCount":317},"100620457","phase-1-a-proof-of-concept-phase-1-study-of-cgb-600-for-the-topical-treatment-of-non-segmented-facial-vitiligo-100620457","NCT07357870","A Proof of Concept, Phase 1 Study of CGB-600 for the Topical Treatment of Non-Segmented Facial Vitiligo","Safety and Effectiveness of CGB-600 Gel for the Treatment of Non-Segmental Facial Vitiligo: A Randomized, Double-Blind, Vehicle-Controlled Phase 1 Proof of Concept Study (Study No. CGB-600-02)","Inclusion Criteria:\n\n1. Adult (18 to 60 years old) diagnosed with non-segmental vitiligo on the face or neck. Dermoscopy and a Wood's Lamp Examination should be performed to confirm the diagnosis.\n2. Facial and\u002For neck involvement with 1-3 vitiligo lesions (total combined area of lesions ≥ 6 cm² and ≤ 40 cm² and ≥75% depigmentation) for at least 3 months (90 days) prior to Baseline.\n3. Vitiligo involvement ≤ 20% total body surface area (BSA).\n4. Is otherwise in good health and free from any disease, condition, or constraint that, in the Investigator's opinion, might interfere with the conduct of the study\n5. Stable disease, as judged by the investigator and patient report. Facial lesions must have been present ≤ 5 years with no new lesions or progression within 90 days prior to Baseline\n6. Is not currently taking any medication for vitiligo in oral, topical, or any other form, including over-the-counter (OTC) and\u002For cosmetic products\n7. Agrees to refrain from any other treatment modalities, including lights, lasers, or other medical devices, prescription or otherwise, for vitiligo for 4 weeks (28 days) before and during the study treatment (see Table 5.1 for complete list)\n8. Agrees to refrain from using any lotions, creams, liquids, or other topical products at the treatment site during the study treatment period unless directed to do so by the investigator\n9. Agrees to review and sign a written informed consent form\n10. Can understand and comply with the study requirements as judged by the investigator\n11. Females of childbearing potential (FOCBP) must have a negative urine pregnancy test and must agree to use a highly effective form of contraception or abstinence and be willing to remain on that same method of birth control throughout the study.\n\n    \\-\n\nExclusion Criteria:\n\n* 1\\. Females who are pregnant, breastfeeding, or of childbearing potential and not practicing reliable birth control\n\n  2\\. History of segmental or mixed vitiligo\n\n  3\\. Vitiligo affecting only external genitalia or hands\u002Ffeet\n\n  4\\. History of skin cancer or pre-cancerous lesions in the treatment area\n\n  5\\. Past use of topical or systemic vitiligo treatments within 4 weeks (28 days) prior to Baseline 6. Current active use of topical corticosteroids on the face or immunomodulatory therapies within 4 weeks (28 days) prior to Baseline\n\n  7\\. Use of biological, investigational, or experimental therapy 3 months before Baseline that could potentially interfere with the study participation or assessment\n\n  8\\. Known hypersensitivity to any components of the intervention or vehicle\n\n  9\\. History of melanocyte-keratinocyte transplantation procedure (MKTP) or other surgical treatments for vitiligo\n\n  10\\. Uncontrolled thyroid function or other medical conditions that could interfere with study participation or assessment\n\n  11\\. Use within 4 weeks (28 days) prior to Baseline (washout period) of 1) oral, intravenous or intralesional corticosteroids, 2) UVA\u002FUVB therapy, 3) non-prescription UV light sources, 4) any oral or topical Janus kinase inhibitor (JAKi), or 5) cytotoxic drugs\n\n  12\\. Has demonstrated resistance to previous JAKi treatment, topical or systemic\n\n  13\\. Has clinically significant laboratory anomalies or vital signs, as judged by the investigator, that would interfere with the conduct or interpretation of study results\n\n  14\\. Has any inflammations or any active skin diseases on the face and\u002For neck including complete leukotrichia or facial lesions that would interfere with study participation or assessment\n\n  15\\. Is currently participating in another investigational medication or device study or has participated in a clinical trial within 30 days of the intended start of study treatment\n\n  16\\. Is unable or unwilling to comply with any of the study requirements\n\n  17\\. Has medical or psychiatric conditions or a personal situation that may increase the risk associated with study participation or may interfere with interpretation of study results or subject compliance and, in the opinion of the Principal Investigator (PI), makes the subject inappropriate for study entry\n\n  18\\. Clinically significant alcohol or drug abuse, or history of poor cooperation or unreliability",{"count":304,"type":22},36,[55],"The goal of this clinical trial is to learn if drug CGB-600 works to treat vitiligo on the face and neck in participants between 18-60 years of age. It will also learn about the safety of CGB-600. The main questions it aims to answer are:\n\nDoes CGB-600 decrease the severity of vitiligo on the face and neck? What medical problems do participants have when taking drug CGB-600? Researchers will compare CGB-600 to a non-active drug (vehicle) to see if CGB-600 works to treat vitiligo.\n\nParticipants will:\n\nApply face twice daily for a period of 24 weeks. Visit the clinic 8 times for checkups and tests.",[28],"2026-01-21",{"date":310,"type":34},"2026-01-22",{"date":312,"type":34},"2025-07-25",{"date":314,"type":22},"2026-11-30",{"name":316,"class":41},"CAGE Bio Inc.",2,{"id":319,"slug":320,"hasResults":12,"nctId":321,"briefTitle":322,"officialTitle":323,"acronym":324,"eligibilityCriteria":325,"healthyVolunteers":12,"sex":17,"minAge":249,"maxAge":4,"enrollmentInfo":326,"targetDuration":4,"studyType":80,"phases":4,"briefSummary":328,"conditions":329,"keywords":334,"overallStatus":60,"whyStopped":4,"lastUpdateSubmitDate":339,"lastUpdatePostDateStruct":340,"startDateStruct":342,"completionDateStruct":344,"leadSponsor":346,"locationsCount":93},"100618824","landscape-demographics-and-treatment-patterns-of-patients-with-immune-mediated-inflammatory-skin-diseases-in-italian-clinical-practice-100618824","NCT07336641","LANDSCAPE: Demographics and Treatment Patterns of Patients With Immune-Mediated Inflammatory Skin Diseases in Italian Clinical Practice","LANDSCAPE - Demographic Characteristics and Treatment Profiles of Patients Affected by Inflammatory Skin Diseases (Psoriasis, Atopic Dermatitis, Alopecia Areata, Vitiligo, Hidradenitis Suppurativa) in Italian Clinical Practice","LANDSCAPE","Inclusion Criteria:\n\n1. Documented diagnosis of psoriasis, atopic dermatitis, vitiligo, alopecia areata, or hidradenitis suppurativa.\n2. Age 12 years or older at the first recorded visit.\n3. Eligible for or treated with systemic therapies.\n4. At least one documented visit during January 2016 to December 2025.\n5. No opt-out exercised.\n\nExclusion Criteria:\n\n1. Opt-out exercised.\n2. Medical records with insufficient data.",{"count":327,"type":22},20000,"This multicenter retrospective observational registry study will collect existing clinical data from Italian centers to describe epidemiology, treatment patterns, clinical evolution, safety, and comorbidities in patients aged 12 years and older with psoriasis, atopic dermatitis, vitiligo, alopecia areata, or hidradenitis suppurativa.",[330,331,28,332,333],"Psoriasis","Atopic Dermatitis","Alopecia Areata","Hidradenitis Suppurativa",[335,336,337,229,338],"Registry","Real-World Evidence","Treatment Patterns","Italy","2026-01-13",{"date":341,"type":34},"2026-01-15",{"date":343,"type":22},"2026-01",{"date":345,"type":22},"2028-01",{"name":347,"class":92},"Fondazione ISIDE",{"id":349,"slug":350,"hasResults":12,"nctId":351,"briefTitle":352,"officialTitle":353,"acronym":4,"eligibilityCriteria":354,"healthyVolunteers":12,"sex":17,"minAge":355,"maxAge":356,"enrollmentInfo":357,"targetDuration":4,"studyType":23,"phases":358,"briefSummary":360,"conditions":361,"keywords":363,"overallStatus":60,"whyStopped":4,"lastUpdateSubmitDate":339,"lastUpdatePostDateStruct":372,"startDateStruct":373,"completionDateStruct":375,"leadSponsor":377,"locationsCount":93},"100616586","nevus-removal-vs-conservative-treatment-in-halo-nevus-with-vitiligo-a-randomized-study-100616586","NCT07307534","Nevus Removal vs. Conservative Treatment in Halo Nevus With Vitiligo: A Randomized Study","Central Nevus Removal Versus Conservative Treatment for Halo Nevus With Vitiligo: A Prospective Randomized Controlled Trial","Inclusion Criteria:\n\n* Patients with halo nevus accompanied by non-segmental vitiligo, with BSA ≤2% (excluding acral regions).\n\n  * Central nevus confirmed as benign melanocytic nevus through clinical observation and dermatoscope.\n\n    * Age 6 to 45 years, regardless of gender ④ Physically able to tolerate surgery and local anesthesia\n\nExclusion Criteria:\n\n* History of keloid formation or hypertrophic scarring (to avoid abnormal hyperplasia at the operative site and interference with repigmentation assessment)\n\n  * Other autoimmune diseases (e.g., hyperthyroidism)\n\n    * Patients with significant endocrine disorders, psychiatric conditions, hematologic diseases, hepatic\u002Frenal disorders, cardiovascular\u002Fcerebrovascular diseases, severe infections, or other major systemic illnesses\n\n      * Use of hormonal medications, immunomodulators, or phototherapy within the past 1 month ⑤ Pregnant or lactating women ⑥ Allergy to anesthetic agents or excipients\n\n        * Poor psychological status or compliance, unable to cooperate with postoperative follow-up or care ⑧ Concurrent conditions requiring other treatments that may interfere with the study observations","6 Years","45 Years",{"count":21,"type":22},[359],"NA","This clinical trial aims to compare the efficacy and safety of central nevus removal versus conservative treatment in patients with halo nevus accompanied by non-segmental vitiligo. It is a single-center, prospective, randomized controlled trial involving 60 participants aged 6 to 45 years, who will be randomly assigned to either the nevus removal group or the conservative treatment group. The removal group will undergo surgical or laser excision of the central nevus followed by medication, while the conservative group will receive medication only. Both groups will be followed for 6 months. Outcomes include repigmentation assessment using vitiligo scoring indices, quality of life measures, and serial serum cytokine profiling. The study seeks to provide high-level evidence to guide clinical management of halo nevus with vitiligo. Key points:\n\n1. For patients with halo nevus accompanied by non-segmental vitiligo.\n2. For patients aged 6 to 45 years.\n3. Compares nevus excision and conservative treatment.\n4. Follows participants for 6 months.\n5. Focuses on effectiveness and safety.",[28,362],"Halo Nevus",[28,364,365,366,231,367,368,369,370,371],"Halo nevus","Randomized Controlled Trial","Tacrolimus","Nevus excision","Treatment comparison","Efficacy","Safety","VASI score",{"date":341,"type":34},{"date":374,"type":22},"2026-01-20",{"date":376,"type":22},"2027-10-01",{"name":215,"class":92},{"id":379,"slug":380,"hasResults":12,"nctId":381,"briefTitle":382,"officialTitle":383,"acronym":4,"eligibilityCriteria":384,"healthyVolunteers":12,"sex":17,"minAge":385,"maxAge":277,"enrollmentInfo":386,"targetDuration":4,"studyType":23,"phases":387,"briefSummary":388,"conditions":389,"keywords":392,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":395,"lastUpdatePostDateStruct":396,"startDateStruct":398,"completionDateStruct":400,"leadSponsor":402,"locationsCount":93},"100480505","phase-4-topical-5-fluorouracil-effervescent-powder-in-the-treatment-of-vitiligo-100480505","NCT05536856","Topical 5-Fluorouracil Effervescent Powder in the Treatment of Vitiligo","Development and Clinical Evaluation of Topical 5-Fluorouracil Effervescent Powder Formulation in the Treatment of Vitiligo","Inclusion Criteria:\n\n* Patients who will be diagnosed as localized stable vitiligo.\n* Age older than 10 years\n* Stability of lesions for a duration of at least 1 year.\n* Patients who didn't receive treatment for vitiligo in the previous 6 weeks before starting the study.\n* Patients who agreed to join the study and signed written consent and continued till the end of the follow up period\n\nExclusion Criteria:\n\n* Patients with vitiligo patches on mucous membrane,\n* Patients with Koebner phenomenon,\n* Other uncontrolled systemic illnesses\n* Patients receiving any systemic or topical treatment for vitiligo","10 Years",{"count":21,"type":22},[252],"A novel approach for 5-Fluorouracil delivery based on a solid effervescent formulation is proposed . 5-Fluorouracil is water soluble (\\~50mg\u002Fml) and therefore has been used for the development of novel topical formulations including nano and microparticles intended for skin targeting. After hydration 5-Fluorouracil could form a complex, a suspension or even be formulated to generate effervescence. In effervescent technology, gas bubbles occur from the liquid after chemical reaction between alkali salts and organic acids (mainly citric or tartaric. Due to liberation in CO2 gas, the dissolution of drug in water is enhanced. The aim of this study is the development and clinical evaluation of topical 5-florouracil effervescent powder formulation in the treatment of vitiligo.",[28,390,391],"Topical Fluorouracil","Effervescent Mixture",[28,393,394],"Fluorouracil","Effervescent powder","2026-01-04",{"date":397,"type":34},"2026-01-06",{"date":399,"type":34},"2022-10-15",{"date":401,"type":22},"2025-12-30",{"name":403,"class":92},"Al-Azhar University",{"id":405,"slug":406,"hasResults":12,"nctId":407,"briefTitle":408,"officialTitle":409,"acronym":4,"eligibilityCriteria":410,"healthyVolunteers":12,"sex":17,"minAge":249,"maxAge":4,"enrollmentInfo":411,"targetDuration":413,"studyType":80,"phases":4,"briefSummary":414,"conditions":415,"keywords":416,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":422,"lastUpdatePostDateStruct":423,"startDateStruct":425,"completionDateStruct":427,"leadSponsor":429,"locationsCount":93},"100604757","a-real-world-study-on-the-influencing-factors-of-efficacy-of-ruxolitinib-cream-in-vitiligo-100604757","NCT07153666","A Real-world Study on the Influencing Factors of Efficacy of Ruxolitinib Cream in Vitiligo","A Real-world Study on the Influencing Factors of the Efficacy of Ruxolitinib Cream in the Treatment of Vitiligo","Inclusion Criteria:\n\n1. Age12 years or older, any gender;\n2. Signed\"Informed Consent Form\";\n3. Clinically diagnosed with non-segmental vitiligo;\n4. Vitiligo area less than 10% of body surface area;\n5. Agreed to discontinue all other vitiligo-related treatments from the screening visit until the final follow-up visit;\n6. Female subjects must not plan for pregnancy or oocyte donation from screening until 4 weeks after the last dose and must voluntarily adopt highly effective physical contraception; male subjects must not plan for fertility or sperm donation during the same period and must voluntarily adopt highly effective physical contraception. Methods include:\n\n   * Barrier methods: Condom or barrier cap (diaphragm or cervical cap);\n   * Intrauterine device (IUD) or intrauterine system (IUS);\n   * Surgical sterilization (bilateral oophorectomy with\u002Fwithout hysterectomy, total hysterectomy, bilateral tubal ligation, or vasectomy) performed ≥6 months prior to the first dose in the subject or their partner;\n   * Other investigator-confirmed highly effective physical contraception.\n\nExclusion Criteria:\n\n1. Allergy to ruxolitinib cream;\n2. Pregnant or lactating women;\n3. Any condition deemed inappropriate for study participation by the investigator.",{"count":412,"type":22},170,"6 Months","Vitiligo is a common chronic autoimmune skin disease that can occur on any part of the body and severely impacts patients' quality of life. Current treatment for vitiligo primarily include topical medications, phototherapy, systemic therapy and surgical interventions, but their efficacy is limited, often failing to achieve ideal therapeutic outcomes, and are associated with a high recurrence rate. This study is an investigator-initiated real-world research on the application of ruxolitinib cream for vitiligo treatment, with the primary objective of exploring the factors influencing the efficacy of ruxolitinib cream in treating vitiligo.",[28],[136,417,418,419,420,421],"JAK","ruxolitinib","treatment","efficacy","influencing factors","2025-12-28",{"date":424,"type":34},"2026-01-02",{"date":426,"type":34},"2025-12-08",{"date":428,"type":22},"2027-12-31",{"name":430,"class":92},"Peking University Third Hospital",{"id":432,"slug":433,"hasResults":12,"nctId":434,"briefTitle":435,"officialTitle":436,"acronym":4,"eligibilityCriteria":437,"healthyVolunteers":76,"sex":17,"minAge":18,"maxAge":438,"enrollmentInfo":439,"targetDuration":4,"studyType":80,"phases":4,"briefSummary":441,"conditions":442,"keywords":4,"overallStatus":60,"whyStopped":4,"lastUpdateSubmitDate":443,"lastUpdatePostDateStruct":444,"startDateStruct":446,"completionDateStruct":447,"leadSponsor":449,"locationsCount":93},"100615895","building-an-assessment-model-for-vitiligo-activity-and-prognosis-using-peripheral-blood-cytokine-profiles-100615895","NCT07298551","Building an Assessment Model for Vitiligo Activity and Prognosis Using Peripheral Blood Cytokine Profiles","Construction of an Assessment Model for Vitiligo Disease Activity and Treatment Prognosis Based on Peripheral Blood Cytokine Profiles","Inclusion Criteria:\n\n* Patients with clinically confirmed vitiligo (diagnosis criteria refer to the Consensus on Vitiligo Diagnosis and Treatment (2018 Edition) established by the Pigment Disorders Group of the Dermatology and Venereology Professional Committee of the Chinese Association of Integrative Medicine) and a healthy control group.\n* Aged 18 years or older, no gender restrictions\n* Possess an elementary school education or higher\n* Voluntarily participate in this study\n\nExclusion Criteria:\n\n* Patients who have used antibiotics, corticosteroids, or immunosuppressants within the past month\n* Patients with severe cardiovascular or cerebrovascular disease, severe diabetes, severe infection, or other major illnesses resulting in poor physical condition\n* Patients with photosensitive disorders, skin tumors, autoimmune diseases, or hematological disorders\n* Pregnant or lactating women\n* Patients with poor psychological stability or compliance who cannot cooperate with follow-up visits or nursing care","80 Years",{"count":440,"type":22},125,"Vitiligo is a chronic autoimmune disorder characterized by depigmented patches on the skin, which can pose significant psychosocial challenges, particularly for individuals with darker skin tones. Compared to the general population, individuals with vitiligo are more likely to experience immune-mediated diseases or psychological comorbidities. Studies confirm that the combined prevalence of depression and anxiety among vitiligo patients reaches 8% and 35.8%, respectively. Notably, the anxiety prevalence rate is comparable to that seen in other severely debilitating skin conditions such as eczema and psoriasis. However, the progression, stability, and recurrence of vitiligo exhibit high unpredictability. Unlike other inflammatory skin diseases such as psoriasis or atopic dermatitis, there is currently a lack of objective, sensitive biological markers in clinical practice to predict disease activity, forecast treatment response, or assess long-term prognosis. Decisions primarily rely on the attending physician's assessment of disease activity, affected areas, severity, and repigmentation potential. Furthermore, clinical signs of active vitiligo are only observable in some active-phase patients, introducing delays and subjectivity. This leads to reactive treatment decisions, increasing the likelihood of missing the optimal intervention window. Cytokines are small-molecule polypeptides or glycoproteins synthesized and secreted by the body's cells, possessing diverse biological activities. They play a central role in physiological and pathological processes such as immune regulation, anti-infection, and anti-tumor responses. The \"Twelve Cytokine Panel\" is a clinical test utilizing advanced flow cytometry for the combined analysis of 12 core cytokines. The cytokines included in this test are IL-1β, IL-2, IL-4, IL-5, IL-6, IL-8, IL-10, IL-12p70, IL-17, IFN-α, IFN-γ, and TNF-α. This panel comprehensively reflects innate immune and T-cell immune responses, providing crucial laboratory evidence for evaluating the functional status of the immune system and inflammatory network. Cytokines serve as core messenger molecules in the autoimmune pathogenesis of vitiligo, forming a complex inflammatory network that governs the entire process of immune attacks against melanocytes. Consequently, detecting specific cytokine profiles not only deepens our understanding of vitiligo's disease mechanisms but also holds immense potential clinical value in assessing disease activity, monitoring treatment efficacy, and developing novel targeted therapies.",[28],"2025-12-21",{"date":445,"type":34},"2025-12-23",{"date":445,"type":22},{"date":448,"type":22},"2027-09-01",{"name":215,"class":92},{"id":451,"slug":452,"hasResults":12,"nctId":453,"briefTitle":454,"officialTitle":455,"acronym":4,"eligibilityCriteria":456,"healthyVolunteers":12,"sex":17,"minAge":457,"maxAge":458,"enrollmentInfo":459,"targetDuration":4,"studyType":23,"phases":460,"briefSummary":461,"conditions":462,"keywords":4,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":463,"lastUpdatePostDateStruct":464,"startDateStruct":466,"completionDateStruct":468,"leadSponsor":470,"locationsCount":93},"100613490","betamethasone-phonophoresis-for-vitiligo-100613490","NCT07267273","Betamethasone Phonophoresis For Vitiligo","Effect of Betamethasone Phonophoresis in Treatment of Vitiligo","Inclusion Criteria:\n\n* Male and female patients diagnosed with vitiligo.\n* Medically and psychologically stable patients.\n* Good cognitive abilities to understand the requirements of the study.\n* All patients enrolled to the study will have their informed consent.\n* they had no contraindications to the use of therapeutic ultrasound\n\nExclusion Criteria:\n\n* Pregnancy or lactation.\n* Immunosuppression.\n* Alcohol abuse.\n* History of spontaneous re-pigmentation of lesions.\n* Presence of skin characteristics that may interfere with study assessment.\n* Active bacterial\u002Fviral infection.\n* Patients on other immune suppressants and phototherapy\n* Patients currently participating in any other clinical study\n* Uncooperative patients.","25 Years","40 Years",{"count":21,"type":22},[359],"Vitiligo is a skin disorder that results in the formation of depigmented patches or hypopigmented macules due to selective destruction or reduction of melanocytes the cells that produce pigment in our skin.\n\nVitiligo affects 0.1-2% of the World's population. People of all skin types and all ages can be affecte. In most of the cases, white patches develop or expand slowly overtime, and in some cases it never progress and remains stable . Vitiligo can be segmental or non-segmental depending upon the morphology of the clinical involvement. It can also be classified as stable or unstable based on the activity of disease.\n\nSteroids act as anti-inflammatory and immunosuppressant agents. Even if different classes of steroids are now available, the mid- potent ones (e.g. betamethasone dipropionate 0.05% cream, 0.05% clobetasol propionate ointment) are usually preferred for the treatment of young patients .\n\nNow days, topical corticosteroids are the most commonly prescribed agents in treatment of dermatologic conditions .Almost all treatments of vitiligo have borrowed from therapies whose prime targets have been another disease.",[28],"2025-11-25",{"date":465,"type":34},"2025-12-05",{"date":467,"type":34},"2025-11-10",{"date":469,"type":22},"2026-02-10",{"name":268,"class":92},{"id":472,"slug":473,"hasResults":12,"nctId":474,"briefTitle":475,"officialTitle":476,"acronym":4,"eligibilityCriteria":477,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":478,"targetDuration":4,"studyType":23,"phases":480,"briefSummary":481,"conditions":482,"keywords":4,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":483,"lastUpdatePostDateStruct":484,"startDateStruct":486,"completionDateStruct":488,"leadSponsor":490,"locationsCount":492},"100585708","phase-1-a-study-to-evaluate-the-safety-and-efficacy-of-fb102-in-patients-with-non-segmental-vitiligo-100585708","NCT06905873","A Study to Evaluate the Safety and Efficacy of FB102 in Patients With Non-segmental Vitiligo","A Randomized, Double-Blind, Placebo Controlled, Multi-center Study to Evaluate the Safety and Efficacy of FB102 in Patients With Non-Segmental Vitiligo","Inclusion Criteria:\n\n1. Males and females aged ≥ 18 to 75 years at time of Screening.\n2. Must have confirmed non-segmental vitiligo criteria at the Screening Visit and the Baseline Visit, as assessed by the study investigator.\n3. If receiving concomitant medications for any reason other than vitiligo, must be on a stable regimen, which is defined as not starting a new drug or changing dosage within 7 days or 5 half-lives (whichever is longer) prior to Day 1. Participant must be willing to stay on a stable regimen during the duration of the study.\n\nNote: There are additional inclusion criteria. The study center will determine if participant meets all of the criteria\n\nExclusion Criteria:\n\n1. Currently have active forms of other hypopigmentation (including but not limited to Vogt-Koyanagi-Harada disease, malignancy-induced hypopigmentation \\[melanoma and mycosis fungoides\\], post-inflammatory hypopigmentation, pityriasis alba \\[minor manifestation of atopic dermatitis\\], senile leukoderma \\[age-related depigmentation\\], chemical\u002Fdrug-induced leukoderma, ataxia telangiectasia, tuberous sclerosis, melasma, and congenital hypopigmentation disorders including piebaldism, Waardenburg syndrome, hypomelanosis of Ito, incontinentia pigmenti, dyschromatosis symmetrica hereditaria, xeroderma pigmentosum, and nevus depigmentosus).\n2. Currently have active forms of inflammatory skin disease(s) or evidence of skin conditions (including but not limited to morphea, discoid lupus, leprosy, syphilis, psoriasis, seborrheic dermatitis) at the time of the Screening or Day 1 Visit that in the opinion of the investigator would interfere with evaluation of vitiligo or response to treatment.\n3. Greater than approximately 33% leukotrichia (depigmentation of the hair) in areas of vitiligo on the face as assessed by a healthcare professional at the time of screening.\n\nNote: There are additional exclusion criteria. The study center will determine if participant meets all of the criteria",{"count":479,"type":22},64,[55],"A Randomized, Double-Blind, Placebo Controlled, Multi-center Study to Evaluate the Safety and Efficacy of FB102 in Patients with Non-Segmental Vitiligo.",[28],"2025-11-17",{"date":485,"type":34},"2025-11-20",{"date":487,"type":34},"2025-03-25",{"date":489,"type":22},"2026-12-31",{"name":491,"class":41},"Forte Biosciences, Inc.",6,{"id":494,"slug":495,"hasResults":12,"nctId":496,"briefTitle":497,"officialTitle":497,"acronym":4,"eligibilityCriteria":498,"healthyVolunteers":12,"sex":17,"minAge":499,"maxAge":51,"enrollmentInfo":500,"targetDuration":4,"studyType":23,"phases":501,"briefSummary":502,"conditions":503,"keywords":504,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":507,"lastUpdatePostDateStruct":508,"startDateStruct":510,"completionDateStruct":512,"leadSponsor":514,"locationsCount":93},"100607386","autologous-non-cultured-epidermal-cell-suspension-transplantation-in-the-treatment-of-vitiligo-100607386","NCT07187882","Autologous Non-cultured Epidermal Cell Suspension Transplantation in the Treatment of Vitiligo","Inclusion Criteria:\n\n* Patients diagnosed as vitiligo, according to the \"Vitiligo Diagnosis and Treatment Consensus (2021 edition)\n* Segmental and unclassified vitiligo stable for 6 months, Non-segmental vitiligo stable for 1 year and resistant to medication and phototherapy\n* BSA≥5%\n* Sign the informed consent and be willing to undergo surgical treatment\n* 8-65 years old, both genders\n\nExclusion Criteria:\n\n* Severe visceral or infectious disease not suitable for surgical treatment\n* Tendency toward keloid formation\n* Coagulation defects\n* Unable to complete follow-up on time","8 Years",{"count":5,"type":22},[359],"To observe the long-term efficacy and safety of autologous non cultured epidermal cell suspension transplantation in the treatment of vitiligo, analyze the correlation between cell density, type, and postoperative efficacy and prognosis, and providing a basis for clinical application.",[28],[505,136,506],"non cultured epidermal cell suspension","autologous","2025-09-16",{"date":509,"type":34},"2025-09-23",{"date":511,"type":34},"2024-04-25",{"date":513,"type":22},"2025-12-31",{"name":515,"class":92},"Peking University People's Hospital",{"id":517,"slug":518,"hasResults":12,"nctId":519,"briefTitle":520,"officialTitle":521,"acronym":4,"eligibilityCriteria":522,"healthyVolunteers":12,"sex":17,"minAge":523,"maxAge":222,"enrollmentInfo":524,"targetDuration":4,"studyType":23,"phases":526,"briefSummary":527,"conditions":528,"keywords":529,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":532,"lastUpdatePostDateStruct":533,"startDateStruct":535,"completionDateStruct":537,"leadSponsor":539,"locationsCount":93},"100592326","phase-4-comparison-of-needling-and-microneedling-plus-phototherapy-in-localized-vitiligo-patients-100592326","NCT06991972","Comparison of Needling and Microneedling Plus Phototherapy in Localized Vitiligo Patients","Puncture to Repigment: A Comparative Analysis Of Needling vs. Microneedling Along With NBUVB in Treatment of Non-Segmental Vitiligo","Inclusion Criteria:\n\n* Both male and female\n* Age 15-60 years\n* Patients having vitiligo for more than 1 year\n\nExclusion Criteria:\n\n* Patients with tendency of keloid formation or hypertrophic scarring\n* Patients with any bleeding disorder, coagulation defect or using anti platelets\n* Any local infection at the treatment site\n* Patients who had received systemic therapy in last 6 months","15 Years",{"count":525,"type":22},80,[252],"This randomized controlled trial aims to compare the efficacy of needling versus microneedling, both followed by narrowband UVB therapy, in achieving repigmentation in patients with localized stable non-segmental vitiligo.",[28,108],[136,530,531],"needling","microneedling","2025-08-25",{"date":534,"type":34},"2025-09-02",{"date":536,"type":34},"2025-03-01",{"date":538,"type":22},"2025-08-31",{"name":540,"class":92},"Khyber Teaching Hospital",{"id":542,"slug":543,"hasResults":12,"nctId":544,"briefTitle":545,"officialTitle":546,"acronym":4,"eligibilityCriteria":547,"healthyVolunteers":12,"sex":17,"minAge":4,"maxAge":4,"enrollmentInfo":548,"targetDuration":4,"studyType":23,"phases":549,"briefSummary":550,"conditions":551,"keywords":4,"overallStatus":60,"whyStopped":4,"lastUpdateSubmitDate":312,"lastUpdatePostDateStruct":552,"startDateStruct":554,"completionDateStruct":556,"leadSponsor":558,"locationsCount":4},"100599729","microneedling-combined-with-topical-crisaborole-2--ointment-in-treatment-of-vitiligo-100599729","NCT07088276","Microneedling Combined With Topical Crisaborole 2 % Ointment in Treatment of Vitiligo.","Microneedling Combined With Topical Crisaborole 2 % Ointment in Treatment of Vitiligo. A Prospective Controlled Trial.","Inclusion Criteria:\n\n* Patients suffer from non-segmental stable vitiligo.\n* Patients who will accept to be included in the study and will sign a written consent.\n\nExclusion Criteria:\n\n* Patients with history of koebnerization or any sign of disease activity.\n* Patients with keloid tendency.\n* Patients with active infection.\n* Pregnant or lactating woman.",{"count":130,"type":22},[359],"The goal of this clinical trial is to learn if topical crisaborole ointment works to treat vitiligo. It will also learn about the safety of the drug. The main questions it aims to answer are:\n\nCan the drug cause repigmentation of vitiligo lesions when used as topical form after microneedling? What medical problems do participants have when the drug used?\n\nParticipants will:\n\nVisit the clinic once every 2 weeks to have the microneedling sessions for 3 months. and also they will have narrow band UVB sessions two times per week.\n\nRecord any side effect they have during or after the sessions.",[28],{"date":553,"type":34},"2025-07-30",{"date":555,"type":22},"2025-08",{"date":557,"type":22},"2026-08",{"name":559,"class":92},"Tanta University",{"id":561,"slug":562,"hasResults":12,"nctId":563,"briefTitle":564,"officialTitle":565,"acronym":4,"eligibilityCriteria":566,"healthyVolunteers":12,"sex":17,"minAge":276,"maxAge":249,"enrollmentInfo":567,"targetDuration":4,"studyType":23,"phases":569,"briefSummary":570,"conditions":571,"keywords":574,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":582,"lastUpdatePostDateStruct":583,"startDateStruct":585,"completionDateStruct":587,"leadSponsor":588,"locationsCount":93},"100585316","oral-tacrolimus-vs-dexamethasone-micro-pulse-therapy-in-pediatric-rapidly-progressing-vitiligo-a-multicenter-rct-100585316","NCT06900777","Oral Tacrolimus vs Dexamethasone Micro-pulse Therapy in Pediatric Rapidly Progressing Vitiligo: A Multicenter RCT","Oral Tacrolimus Capsule Versus Dexamethasone Micro-pulse Therapy for the Treatment of Rapidly Progressing Vitiligo in Children: A Multicenter, Randomized, Controlled Study","Inclusion Criteria:\n\n* Children aged 4-12 years diagnosed with rapidly progressive non-segmental vitiligo (VIDA score ≥4, indicating disease progression within the past 6 weeks).\n\nTotal body surface area (BSA) affected by vitiligo between 1% and 50%. Guardians provide written informed consent for the child's participation.\n\nExclusion Criteria:\n\n* Stable-phase childhood vitiligo. Segmental, mucosal, undetermined, or generalized vitiligo. Systemic immunosuppressive therapy within the past 4 weeks. Known hypersensitivity to tacrolimus, other macrolide drugs, or study drug excipients.\n\nComorbidities precluding oral tacrolimus use (e.g., severe hepatic\u002Frenal dysfunction).\n\nObesity or systemic diseases (e.g., tuberculosis, acute\u002Fchronic infections, hypertension, congenital cardiovascular disease).\n\nAny condition deemed by investigators to increase participant risk or interfere with trial execution.",{"count":568,"type":22},90,[359],"This clinical study aims to compare the safety and effectiveness of two treatments-oral Tacrolimus capsules and Dexamethasone micro-pulse therapy-in children aged 4-12 years with rapidly progressing vitiligo. The study is a multicenter, randomized, controlled trial involving 90 participants, who will be divided equally into two groups. One group will receive daily Tacrolimus, while the other will take Dexamethasone on weekends. Over 24 weeks, doctors will monitor improvements in skin repigmentation, side effects, and overall health through regular check-ups and blood tests. The goal is to determine which treatment better controls disease progression and improves quality of life for children with vitiligo.\n\nKey Points:\n\n* For children with rapidly spreading vitiligo.\n* Compares two common medications.\n* Follows participants for 6 months.\n* Focuses on safety and effectiveness.",[28,572,573],"Child","Progressive Disease",[366,575,576,577,28,370,369,578,579,580,581],"Dexamethasone","Randomized Controlled Trialy","Children","Multicenter Study","VASI Score","IGA Score","Immunosuppressive Therapy","2025-06-16",{"date":584,"type":34},"2025-06-19",{"date":586,"type":34},"2025-04-01",{"date":208,"type":22},{"name":215,"class":92},{"id":590,"slug":591,"hasResults":12,"nctId":592,"briefTitle":593,"officialTitle":594,"acronym":595,"eligibilityCriteria":596,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":597,"targetDuration":4,"studyType":23,"phases":598,"briefSummary":599,"conditions":600,"keywords":601,"overallStatus":60,"whyStopped":4,"lastUpdateSubmitDate":605,"lastUpdatePostDateStruct":606,"startDateStruct":608,"completionDateStruct":610,"leadSponsor":612,"locationsCount":93},"100590995","the-value-of-using-mini-oral-pulse-steroid-therapy-along-with-non-cultured-epidermal-cell-suspension-nces-in-stable-resistant-vitiligo-100590995","NCT06974669","The Value of Using Mini-oral Pulse Steroid Therapy Along With Non Cultured Epidermal Cell Suspension (NCES) in Stable Resistant Vitiligo","The Value of Using Mini-oral Pulse Steroid Therapy Along With Non Cultured Epidermal Cell Suspension in Stable Resistant Vitiligo: An Interventional Prospective Controlled Trial.","NCES","Inclusion Criteria:\n\n* Patients with non-segmental vitiligo (NSV) with acral or resistant lesions over the elbows and knees, that has not responded to conventional treatment\n* Stability for ≥ 1 year\n* Age ≥18 years\n* Lack of topical treatment for at least 1 month prior to surgery and systemic treatment for at least 3 months prior to surgery.\n\nExclusion Criteria:\n\n* Non acral NSV responsive to conventional treatment modalities\n* Active vitiligo; new lesions, expansion of old lesions, confetti like lesions, ill-defined edges or koebnerization in \\\u003C 1 year\n* Age \\\u003C 18 years.\n* Pregnant females.\n* Patients with hypertension, diabetes or tuberculosis\n* Topical treatment in the past month and systemic treatment in the past 3 months.",{"count":279,"type":22},[359],"Assessing the additive value of mini-oral pulse steroid therapy in surgical treatment of acral and difficult to treat sites of vitiligo",[28],[136,602,603,604],"surgery","mini-oral pulse steroid therapy","resistant","2025-05-08",{"date":607,"type":34},"2025-05-16",{"date":609,"type":22},"2025-05-12",{"date":611,"type":22},"2025-10-01",{"name":268,"class":92},{"id":614,"slug":615,"hasResults":12,"nctId":616,"briefTitle":617,"officialTitle":618,"acronym":4,"eligibilityCriteria":619,"healthyVolunteers":12,"sex":17,"minAge":4,"maxAge":4,"enrollmentInfo":620,"targetDuration":4,"studyType":23,"phases":621,"briefSummary":622,"conditions":623,"keywords":624,"overallStatus":60,"whyStopped":4,"lastUpdateSubmitDate":627,"lastUpdatePostDateStruct":628,"startDateStruct":630,"completionDateStruct":632,"leadSponsor":634,"locationsCount":4},"100588797","immunomodulatory-effects-of-nb-uvb-and-steroids-in-vitiligo-a-study-on-cxcl11-and-temra-biomarkers-100588797","NCT06946069","Immunomodulatory Effects of NB-UVB and Steroids in Vitiligo: A Study on CXCL11 and TEMRA Biomarkers","Expression of CXCL11 & TEMRA in Serum of Vitiligo Patients Treated With Narrow-band UVB","Inclusion Criteria:\n\nClinically diagnosed non-segmental vitiligo (stable for ≥3 months).\n\nFitzpatrick skin types III-V (common in the Egyptian population).\n\nNo recent systemic therapy for vitiligo (within the last 3 months).\n\nExclusion Criteria:\n\nPhotosensitivity disorders (e.g., lupus, porphyria).\n\nPregnancy or breastfeeding.\n\nActive infections, malignancies, or immunosuppressive conditions.\n\nHistory of hypertrophic scarring or melanoma.",{"count":279,"type":22},[359],"this is a prospective, randomized controlled trial (RCT) investigating the immunological effects of narrowband UVB (NB-UVB) phototherapy-both as monotherapy and in combination with oral mini-pulse (OMP) steroids-in non-segmental vitiligo patients. The study evaluates changes in CXCL11 (a chemokine involved in T-cell recruitment) and TEMRA (terminally differentiated effector memory T cells re-expressing CD45RA) levels in serum before and after treatment.",[28,231],[136,231,625,626],"CXCL11","TEMRA","2025-04-19",{"date":629,"type":34},"2025-04-27",{"date":631,"type":22},"2025-09-01",{"date":633,"type":22},"2026-09-30",{"name":635,"class":92},"Assiut University"]